Stryker Co. (NYSE:SYK) Shares Sold by Davis Rea LTD.

Davis Rea LTD. lowered its holdings in shares of Stryker Co. (NYSE:SYK) by 9.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 30,301 shares of the medical technology company’s stock after selling 3,323 shares during the period. Stryker makes up approximately 5.5% of Davis Rea LTD.’s holdings, making the stock its 8th largest holding. Davis Rea LTD.’s holdings in Stryker were worth $10,935,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of SYK. J. W. Coons Advisors LLC increased its stake in shares of Stryker by 0.7% in the fourth quarter. J. W. Coons Advisors LLC now owns 3,653 shares of the medical technology company’s stock worth $1,315,000 after acquiring an additional 26 shares during the last quarter. Opal Wealth Advisors LLC boosted its position in Stryker by 1.6% during the fourth quarter. Opal Wealth Advisors LLC now owns 1,816 shares of the medical technology company’s stock worth $654,000 after purchasing an additional 28 shares during the period. Capital & Planning LLC boosted its holdings in Stryker by 3.6% during the fourth quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock valued at $304,000 after acquiring an additional 29 shares during the period. Alhambra Investment Management LLC boosted its stake in Stryker by 1.5% during the 4th quarter. Alhambra Investment Management LLC now owns 1,997 shares of the medical technology company’s stock valued at $719,000 after purchasing an additional 29 shares during the period. Finally, JFS Wealth Advisors LLC grew its stake in shares of Stryker by 4.4% in the fourth quarter. JFS Wealth Advisors LLC now owns 687 shares of the medical technology company’s stock worth $247,000 after acquiring an additional 29 shares during the last quarter. 77.09% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total transaction of $941,586.06. Following the transaction, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on the stock. Royal Bank of Canada boosted their price target on shares of Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a report on Wednesday, January 29th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday, February 18th. Needham & Company LLC reiterated a “buy” rating and issued a $442.00 price objective on shares of Stryker in a research report on Wednesday, January 29th. Argus set a $450.00 target price on shares of Stryker in a research report on Monday, February 3rd. Finally, Citigroup reissued a “buy” rating and issued a $450.00 target price on shares of Stryker in a research note on Wednesday. Five analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to MarketBeat, Stryker currently has a consensus rating of “Moderate Buy” and a consensus price target of $422.15.

Stryker Price Performance

Shares of SYK stock opened at $389.10 on Friday. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19. The business’s 50 day moving average price is $380.06 and its 200-day moving average price is $370.50. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market cap of $148.47 billion, a P/E ratio of 50.14, a P/E/G ratio of 2.93 and a beta of 0.96.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same quarter last year, the company posted $3.46 earnings per share. On average, equities research analysts anticipate that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a dividend of $0.84 per share. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. The ex-dividend date of this dividend is Monday, March 31st. Stryker’s dividend payout ratio is presently 43.30%.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.